PL2001892T3 - Imidazolotiazolowe związki do leczenia chorób proliferacyjnych - Google Patents

Imidazolotiazolowe związki do leczenia chorób proliferacyjnych

Info

Publication number: PL2001892T3
Authority: PL; Poland
Prior art keywords: treatment; proliferative diseases; imidazolothiazole compounds; imidazolothiazole; compounds
Prior art date: 2006-03-17

Application number

PL07753256T

Other languages

English (en)

Inventor

Shripad Bhagwat

Qi Chao

Robert M Grotzfeld

Hitesh K Patel

Kelly G Sprankle

Original Assignee

Ambit Biosciences Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-03-17

Filing date

2007-03-16

Publication date

2013-09-30

2007-03-16 Application filed by Ambit Biosciences Corp filed Critical Ambit Biosciences Corp

2013-09-30 Publication of PL2001892T3 publication Critical patent/PL2001892T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Oncology (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Transplantation (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Dermatology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

PL07753256T 2006-03-17 2007-03-16 Imidazolotiazolowe związki do leczenia chorób proliferacyjnych PL2001892T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US74354306P	2006-03-17	2006-03-17
EP20070753256 EP2001892B1 (en)	2006-03-17	2007-03-16	Imidazolothiazole compounds for the treatment of proliferative diseases
PCT/US2007/006613 WO2007109120A2 (en)	2006-03-17	2007-03-16	Imidazolothiazole compounds for the treatment of disease

Publications (1)

Publication Number	Publication Date
PL2001892T3 true PL2001892T3 (pl)	2013-09-30

Family

ID=38522967

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL07753256T PL2001892T3 (pl)	2006-03-17	2007-03-16	Imidazolotiazolowe związki do leczenia chorób proliferacyjnych

Country Status (22)

Country	Link
US (6)	US7820657B2 (pl)
EP (1)	EP2001892B1 (pl)
JP (2)	JP4610668B2 (pl)
KR (2)	KR101549364B1 (pl)
CN (1)	CN101448843B (pl)
AU (1)	AU2007227495B2 (pl)
BR (1)	BRPI0708823B1 (pl)
CA (1)	CA2646437C (pl)
DK (1)	DK2001892T3 (pl)
ES (1)	ES2422890T3 (pl)
IL (1)	IL194076A (pl)
MX (1)	MX2008011684A (pl)
MY (1)	MY145070A (pl)
NO (1)	NO342985B1 (pl)
NZ (1)	NZ571566A (pl)
PL (1)	PL2001892T3 (pl)
PT (1)	PT2001892E (pl)
RU (1)	RU2441011C2 (pl)
SI (1)	SI2001892T1 (pl)
TW (1)	TWI409267B (pl)
WO (1)	WO2007109120A2 (pl)
ZA (1)	ZA200808178B (pl)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101549364B1 (ko) *	2006-03-17	2015-09-01	암비트 바이오사이언시즈 코포레이션	질환 치료용 이미다졸로티아졸 화합물
MX2010002295A (es) *	2007-09-19	2010-03-22	Ambit Biosciences Corp	Formas solidas que comprenden n-(5-ter-butil-isoxazol-3-il)-n´-{4- [7-(2-morfolin-4-il-etoxi) imidazo [2,1-b]-[1,3] benzotiazol-2-il] fenil} urea, composiciones de las mismas, y usos de las mismas.
AR069244A1 (es) *	2007-11-08	2010-01-06	Ambit Biosciences Corp	Metodos para administrar n-( 5- ter- butil- isoxixasol-3-il) -n'- (4(7-(2- morfolin-4-il- etoxi) imidazo (2,1-b) (1,3) benzotiazol -2-il) fenil) urea para tratar una enfermedad proliferante y composicion farmaceutica
US7825214B2 (en) *	2008-01-15	2010-11-02	Johns Manville	Purified styrene-maleic anhydride polymer binder
WO2010054058A1 (en) *	2008-11-06	2010-05-14	Ambit Bioscience Corporation	Imidazolothiazole compounds as modulators of protein kinase
EP2218464A1 (en) *	2009-02-11	2010-08-18	Technische Universität München	Compounds for non-invasive measurement of aggregates of amyloid peptides
AU2010228982B2 (en)	2009-03-23	2015-05-14	Ambit Biosciences Corporation	Methods of treatment using combination therapy
SMT202000092T1 (it) *	2009-05-14	2020-05-08	Ambit Biosciences Corp	Formulazione essiccata a spruzzo o liofilizzata di ac220
EP2305688A1 (en)	2009-09-28	2011-04-06	Université de la Méditerranée - Aix-Marseille II	Novel aminoacids derivatives, their process of preparation and their therapeutical uses as MET inhibitors
JP5762426B2 (ja)	2009-11-05	2015-08-12	アムビトビオスシエンセスコルポラチオン	イミダゾ［２，１−ｂ］［１，３］ベンゾチアゾール誘導体の調製方法
WO2011056764A1 (en) *	2009-11-05	2011-05-12	Ambit Biosciences Corp.	Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
HUE045270T2 (hu)	2010-01-05	2019-12-30	Inst Nat Sante Rech Med	FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére
DK2918588T3 (en)	2010-05-20	2017-08-28	Array Biopharma Inc	Macrocyclic compounds as TRK kinase inhibitors
DE102011113749A1 (de) *	2011-09-14	2013-03-14	Aicuris Gmbh & Co. Kg	Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole
PT2766359T (pt) *	2011-10-14	2016-07-14	Ambit Biosciences Corp	Compostos heterocíclicos e utilização dos mesmos como moduladores de recetores tirosina-cinase de tipo iii
CN103172648B (zh)	2011-12-20	2016-05-25	上海迪诺医药科技有限公司	三杂环衍生物、制备方法及应用
RU2632253C2 (ru) *	2012-04-17	2017-10-04	Фуджифилм Корпорэйшн	Азотсодержащее гетероциклическое соединение или его соль
JP6116847B2 (ja)	2012-10-01	2017-04-19	アムビトバイオサイエンシスコーポレーションＡｍｂｉｔＢｉｏｓｃｉｅｎｃｅｓＣｏｒｐｏｒａｔｉｏｎ	シクロデキストリンとの混合体を含有する錠剤
CN104513259B (zh) *	2013-09-26	2017-06-16	广东东阳光药业有限公司	取代脲衍生物及其在药物中的应用
CN104513258B (zh) *	2013-09-26	2018-04-03	广东东阳光药业有限公司	取代脲衍生物及其在药物中的应用
WO2015056683A1 (ja)	2013-10-16	2015-04-23	富士フイルム株式会社	含窒素複素環化合物の塩またはその結晶、医薬組成物およびｆｌｔ３阻害剤
GB201321728D0 (en) *	2013-12-09	2014-01-22	Ucb Pharma Sa	Therapeutic agents
GB201321730D0 (en) *	2013-12-09	2014-01-22	Ucb Pharma Sa	Therapeutic agents
MX385778B (es)	2014-04-04	2025-03-18	Del Mar Pharmaceuticals	Uso de dianhidrogalactitol y análogos o derivados del mismo para tratar cáncer de células no pequeñas del pulmón y cáncer de ovario.
DK3169671T3 (da)	2014-07-17	2019-09-23	Sunshine Lake Pharma Co Ltd	1-(5-(tert.-butyl)isoxazol-3-yl)-3-(4-((phenyl)ethynyl)phenyl)ureaderivater og relaterede forbindelser som flt3-inhibitorer til behandling af kræft
CN107001283B (zh)	2014-07-31	2021-05-25	国家健康与医学研究院	Flt3受体拮抗剂
RU2727195C2 (ru)	2014-08-22	2020-07-21	Фуджифилм Корпорэйшн	Фармацевтическая композиция для лечения злокачественной опухоли, положительной по мутации flt3, ингибитор мутантного flt3 и их применение
BR112017004897A2 (pt) *	2014-09-10	2017-12-12	Glaxosmithkline Ip Dev Ltd	compostos inovadores como inibidores rearranjados durante a transfecção (ret)
CN105461709B (zh) *	2014-09-26	2020-01-21	广东东阳光药业有限公司	取代脲衍生物及其在药物中的应用
CN105801602B (zh) *	2014-12-31	2018-05-04	四川大学	5-叔丁基异噁唑-3-基-3-(4-取代苯基)脲衍生物及其制备方法和用途
CN107427501B (zh)	2015-02-20	2023-12-01	第一三共株式会社	通过联合使用治疗癌症的方法
JP6412471B2 (ja)	2015-07-15	2018-10-24	富士フイルム株式会社	含窒素複素環化合物の製造方法およびその中間体
ES2857081T3 (es)	2015-07-16	2021-09-28	Array Biopharma Inc	Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
CN114377137A (zh)	2016-03-15	2022-04-22	奥莱松基因组股份有限公司	用于治疗血液恶性肿瘤的lsd1抑制剂的组合
EP3254698A1 (en)	2016-06-08	2017-12-13	Universite De Montpellier	Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
JOP20190077A1 (ar)	2016-10-10	2019-04-09	Array Biopharma Inc	مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh)	2016-10-10	2020-09-11	美商亞雷生物製藥股份有限公司	作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136663A1 (en)	2017-01-18	2018-07-26	Array Biopharma, Inc.	Ret inhibitors
ES2948194T3 (es)	2017-01-18	2023-09-01	Array Biopharma Inc	Compuestos de pirazolo[1,5-a]pirazina sustituida como inhibidores de la cinasa RET
JOP20190213A1 (ar)	2017-03-16	2019-09-16	Array Biopharma Inc	مركبات حلقية ضخمة كمثبطات لكيناز ros1
US20200171022A1 (en)	2017-05-17	2020-06-04	Inserm (Institut National De La Santé Et Da La Recherche Médicale)	Flt3 inhibitors for improving pain treatments by opioids
TWI876442B (zh)	2017-10-10	2025-03-11	美商絡速藥業公司	6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh)	2017-10-10	2023-02-01	美商亞雷生物製藥股份有限公司	6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CA3087354C (en)	2018-01-18	2023-01-03	Array Biopharma Inc.	Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
JP6997876B2 (ja)	2018-01-18	2022-02-04	アレイバイオファーマインコーポレイテッド	Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物
EP3740490A1 (en)	2018-01-18	2020-11-25	Array Biopharma, Inc.	Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
ES2922314T3 (es)	2018-09-10	2022-09-13	Array Biopharma Inc	Compuestos heterocíclicos condensados como inhibidores de cinasa RET
IT201900015030A1 (it) *	2019-08-26	2021-02-26	Univ Degli Studi Di Palermo	Nuovi agenti terapeutici per il trattamento di patologie ematologiche
CN113966331B (zh) *	2020-03-11	2024-04-12	暨南大学	含脲结构的三芳环化合物及其应用
CN111362972B (zh) *	2020-04-28	2021-08-24	江南大学	一种苯并咪唑并[2,1-b]噻唑类化合物及其应用
IL279972A (en) *	2021-01-05	2022-08-01	Anima Biotech Inc	C-myc mrna translation modulators and uses thereof in the treatment of cancer
US12404283B2 (en)	2022-07-03	2025-09-02	Anima Biotech Inc.	c-MYC mRNA translation modulators and uses thereof in the treatment of cancer
IL316805A (en) *	2022-07-03	2025-01-01	Anima Biotech Inc	Substances that function as modulators of cMYC-mRNA translation and their uses in cancer treatment
CN115650978A (zh) *	2022-10-16	2023-01-31	河南师范大学	一种7-烷氧基二氢咪唑并[4,5-b]哌啶-2-硫酮类化合物的合成方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL129432C (pl)	1964-02-29
NL129626C (pl)	1964-04-08
US3210370A (en)	1964-06-22	1965-10-05	Upjohn Co	Process for preparing 2, 2'-methylene-bisareneimiazoles
FR2463774A1 (fr)	1979-08-21	1981-02-27	Yamanouchi Pharma Co Ltd	Derives du 2-phenylimidazo(2,1-b)benzothiazole
US4354970A (en)	1980-03-07	1982-10-19	Eastman Kodak Company	Indoline coupled isothiazole azo dyes
JPS56138196A (en)	1980-03-29	1981-10-28	Yamanouchi Pharmaceut Co Ltd	Imidazo (2,1-b)benzothiazole derivative
JPS5740492A (en)	1980-08-22	1982-03-06	Yamanouchi Pharmaceut Co Ltd	Novel 2-phenylimidazo 2,1-b benzothiazole derivative
JPS57149288A (en)	1981-03-12	1982-09-14	Yamanouchi Pharmaceut Co Ltd	Imidazo(2,1-b)benzothiazole derivative
EP0082715A3 (en) *	1981-12-21	1984-01-11	Viragate Limited	A target apparatus
US4464384A (en) *	1981-12-23	1984-08-07	Yamanouchi Pharmaceutical Co., Ltd.	2-Phenylimidazo[2,1-b]benzothiazole compounds, salts thereof, process of producing them, and pharmaceutical compositions containing them
JPS5978194A (ja) *	1982-10-27	1984-05-04	Yamanouchi Pharmaceut Co Ltd	２−フエニルイミダゾ〔２，１−ｂ〕ベンゾチアゾ−ルの新規誘導体およびその製造法
US5236952A (en)	1986-03-11	1993-08-17	Hoffmann-La Roche Inc.	Catechol derivatives
US4880824A (en)	1987-09-21	1989-11-14	Ortho Pharmaceutical Corporation	Phenyl and benzoyl substituted imidazo-fused heterocyclic calcium channel blockers
EP0524055A1 (fr)	1991-07-19	1993-01-20	Synthelabo	Dérivés d'imidazo[2,1-b]benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique
JPH05107705A (ja)	1991-10-17	1993-04-30	Konica Corp	新規な写真用カプラー
ATE172975T1 (de)	1992-05-19	1998-11-15	Adir	Benzimidezolderivate mit antidiabetischer und anti-plättchenklumpungswirkung
FR2699920B1 (fr)	1992-12-24	1995-02-10	Synthelabo	Dérivés d'imidazo [2,1-b] benzothiazole-3-acétamide, leur préparation et leur application en thérapeutique.
FR2700546B1 (fr)	1993-01-15	1995-02-17	Synthelabo	Dérivés d'imidazo[2,1-b]benzoxazole-3-acétamide, leur préparation et leur application en thérapeutique.
EP0607076A1 (fr) *	1993-01-15	1994-07-20	Synthelabo	Dérivés de 9h-imidazo 1,2-a benzimidazole-3-acétamide à activité GABA
JPH07291976A (ja)	1994-04-27	1995-11-07	Otsuka Pharmaceut Factory Inc	イミダゾ〔２，１−ｂ〕チアゾール誘導体
FR2722501B1 (fr)	1994-07-13	1996-08-09	Synthelabo	Derives de 9h-imidazo(1,2-a)benzimidazole-3-acetamide, leur preparation et leur application en therapeutique
US5466799A (en) *	1994-08-08	1995-11-14	Iowa State University Research Foundation, Inc.	Synthesis of benzodiazepines
US5919799A (en)	1995-03-13	1999-07-06	Nikken Chemicals Co., Ltd.	Imidazothiazole compound
WO1998006724A1 (fr)	1996-08-09	1998-02-19	Yamanouchi Pharmaceutical Co., Ltd.	Agonistes du recepteur du glutamate metabotropique
FR2759698B1 (fr)	1997-02-20	1999-03-19	Synthelabo	Derives de 1,4-diphenylimidazole-5-acetamide, leur preparation et leur application en therapeutique
JPH11106340A (ja) *	1997-10-02	1999-04-20	Sumitomo Pharmaceut Co Ltd	Ｓｔａｔ６活性化阻害剤
CN1149085C (zh)	1997-12-22	2004-05-12	拜尔有限公司	用取代杂环脲抑制raf激酶
DE19805117A1 (de)	1998-02-09	1999-08-12	Bayer Ag	Neue Oxazolidinone mit azolhaltigen Tricyclen
DE19905278A1 (de)	1999-02-09	2000-08-10	Bayer Ag	Oxazolidinone und ihre Verwendung als antibakterielle Mittel
GB2351081A (en)	1999-06-18	2000-12-20	Lilly Forschung Gmbh	Pharmaceutically active imidazoline compounds and analogues thereof
JP2001048786A (ja) *	1999-08-05	2001-02-20	Yamanouchi Pharmaceut Co Ltd	三環式ヘテロアリール誘導体
DE19948434A1 (de)	1999-10-08	2001-06-07	Gruenenthal Gmbh	Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
JP2001192386A (ja)	1999-10-29	2001-07-17	Meiji Seika Kaisha Ltd	新規トリアゾール誘導体及びこれを有効成分とする抗真菌剤
DE10019714A1 (de)	2000-04-20	2002-01-10	Gruenenthal Gmbh	Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen
CA2415815A1 (en)	2000-07-06	2002-01-17	Nigel H. Greig	Tetrahydrobenzothiazole analogues as neuroprotective agents
US6696441B1 (en)	2000-08-11	2004-02-24	The Regents Of The University Of California	Inhibition of p53-induced stress response
US7601846B2 (en)	2001-06-26	2009-10-13	The Regents Of The University Of California	Compounds having activity as inhibitors of apoptosis
US20030143199A1 (en)	2001-10-09	2003-07-31	Carson Dennis A.	Use of STAT-6 inhibitors as therapeutic agents
US20040127719A1 (en)	2002-03-08	2004-07-01	Kexin Yang	Alpha-isocyanocarboxylate solid support templates, method of preparation and for using the same
MXPA05005474A (es)	2002-11-25	2005-07-25	Pharmacia Corp	Acidos y amidas heteroarilsulfonilmetil hidroxamicos y su uso como inhibidores de proteasas.
CA2509561A1 (en)	2002-12-18	2004-07-15	Mallinckrodt Inc.	Synthesis of heteroaryl acetamides
KR100647583B1 (ko)	2003-10-07	2006-11-17	삼성에스디아이 주식회사	이미다졸 고리 함유 화합물 및 이를 이용한 유기 전계발광 소자
US20050171172A1 (en)	2003-11-13	2005-08-04	Ambit Biosciences Corporation	Amide derivatives as PDGFR modulators
KR101549364B1 (ko) *	2006-03-17	2015-09-01	암비트 바이오사이언시즈 코포레이션	질환 치료용 이미다졸로티아졸 화합물
MX2010002295A (es)	2007-09-19	2010-03-22	Ambit Biosciences Corp	Formas solidas que comprenden n-(5-ter-butil-isoxazol-3-il)-n´-{4- [7-(2-morfolin-4-il-etoxi) imidazo [2,1-b]-[1,3] benzotiazol-2-il] fenil} urea, composiciones de las mismas, y usos de las mismas.
AR069244A1 (es)	2007-11-08	2010-01-06	Ambit Biosciences Corp	Metodos para administrar n-( 5- ter- butil- isoxixasol-3-il) -n'- (4(7-(2- morfolin-4-il- etoxi) imidazo (2,1-b) (1,3) benzotiazol -2-il) fenil) urea para tratar una enfermedad proliferante y composicion farmaceutica
WO2010054058A1 (en) *	2008-11-06	2010-05-14	Ambit Bioscience Corporation	Imidazolothiazole compounds as modulators of protein kinase
AU2010228982B2 (en) *	2009-03-23	2015-05-14	Ambit Biosciences Corporation	Methods of treatment using combination therapy
SMT202000092T1 (it) *	2009-05-14	2020-05-08	Ambit Biosciences Corp	Formulazione essiccata a spruzzo o liofilizzata di ac220

2007
- 2007-03-16 KR KR1020147018402A patent/KR101549364B1/ko active Active
- 2007-03-16 SI SI200731239T patent/SI2001892T1/sl unknown
- 2007-03-16 US US11/724,992 patent/US7820657B2/en active Active
- 2007-03-16 TW TW96109141A patent/TWI409267B/zh active
- 2007-03-16 CN CN2007800177601A patent/CN101448843B/zh active Active
- 2007-03-16 CA CA2646437A patent/CA2646437C/en active Active
- 2007-03-16 MX MX2008011684A patent/MX2008011684A/es active IP Right Grant
- 2007-03-16 BR BRPI0708823-0A patent/BRPI0708823B1/pt active IP Right Grant
- 2007-03-16 WO PCT/US2007/006613 patent/WO2007109120A2/en active Application Filing
- 2007-03-16 MY MYPI20083616 patent/MY145070A/en unknown
- 2007-03-16 PT PT77532562T patent/PT2001892E/pt unknown
- 2007-03-16 KR KR1020087025308A patent/KR101449057B1/ko active Active
- 2007-03-16 AU AU2007227495A patent/AU2007227495B2/en active Active
- 2007-03-16 DK DK07753256T patent/DK2001892T3/da active
- 2007-03-16 NZ NZ571566A patent/NZ571566A/en unknown
- 2007-03-16 EP EP20070753256 patent/EP2001892B1/en active Active
- 2007-03-16 PL PL07753256T patent/PL2001892T3/pl unknown
- 2007-03-16 ES ES07753256T patent/ES2422890T3/es active Active
- 2007-03-16 RU RU2008141169A patent/RU2441011C2/ru active
- 2007-03-16 JP JP2009500500A patent/JP4610668B2/ja active Active
2008
- 2008-09-14 IL IL194076A patent/IL194076A/en active IP Right Grant
- 2008-09-25 ZA ZA2008/08178A patent/ZA200808178B/en unknown
- 2008-10-17 NO NO20084374A patent/NO342985B1/no unknown
2010
- 2010-08-04 US US12/850,557 patent/US8129374B2/en active Active
- 2010-08-31 JP JP2010194909A patent/JP5395017B2/ja active Active
2012
- 2012-01-24 US US13/357,477 patent/US8557810B2/en active Active
2013
- 2013-09-20 US US14/033,299 patent/US8921546B2/en active Active
2014
- 2014-10-31 US US14/530,383 patent/US20150126505A1/en not_active Abandoned
2017
- 2017-06-26 US US15/633,620 patent/US20170348320A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL194076A (en)	2015-05-31
IL194076A0 (en)	2009-09-22
US8557810B2 (en)	2013-10-15
PT2001892E (pt)	2013-07-04
CA2646437A1 (en)	2007-09-27
EP2001892B1 (en)	2013-04-24
ZA200808178B (en)	2010-11-24
BRPI0708823B1 (pt)	2022-01-18
SI2001892T1 (sl)	2013-07-31
US20100298313A1 (en)	2010-11-25
KR20140091619A (ko)	2014-07-21
KR101449057B1 (ko)	2014-10-10
DK2001892T3 (da)	2013-07-01
CN101448843A (zh)	2009-06-03
NO342985B1 (no)	2018-09-17
US7820657B2 (en)	2010-10-26
AU2007227495B2 (en)	2013-02-21
US20170348320A1 (en)	2017-12-07
US20120129850A1 (en)	2012-05-24
TWI409267B (zh)	2013-09-21
EP2001892A2 (en)	2008-12-17
US20070232604A1 (en)	2007-10-04
KR101549364B1 (ko)	2015-09-01
US20140243525A1 (en)	2014-08-28
NZ571566A (en)	2011-07-29
BRPI0708823A2 (pt)	2011-06-14
US20150126505A1 (en)	2015-05-07
CN101448843B (zh)	2012-05-09
WO2007109120A2 (en)	2007-09-27
AU2007227495A1 (en)	2007-09-27
KR20080108548A (ko)	2008-12-15
RU2008141169A (ru)	2010-04-27
JP2011037858A (ja)	2011-02-24
WO2007109120A3 (en)	2007-12-27
JP2009530300A (ja)	2009-08-27
RU2441011C2 (ru)	2012-01-27
TW200801021A (en)	2008-01-01
MY145070A (en)	2011-12-15
MX2008011684A (es)	2008-12-12
HK1131141A1 (en)	2010-01-15
NO20084374L (no)	2008-11-05
US8921546B2 (en)	2014-12-30
JP5395017B2 (ja)	2014-01-22
CA2646437C (en)	2016-05-17
ES2422890T3 (es)	2013-09-16
US8129374B2 (en)	2012-03-06
JP4610668B2 (ja)	2011-01-12

Publication	Publication Date	Title
PL2001892T3 (pl)	2013-09-30	Imidazolotiazolowe związki do leczenia chorób proliferacyjnych
IL200862A0 (en)	2010-05-17	3-imidazolyl-indoles for the treatment of proliferative diseases
EP2063897A4 (en)	2010-09-29	KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES
EP2063896A4 (en)	2010-09-29	KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES
IL185016A0 (en)	2007-12-03	Compounds for the treatment of proliferative disorders
IL195571A0 (en)	2009-09-01	Compounds for the treatment of periodontal disease
ZA200906129B (en)	2010-11-24	Compounds for the treatment of hepatitis c
ZA201000106B (en)	2011-06-29	Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
ZA201000087B (en)	2011-06-29	Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
ZA200707591B (en)	2009-08-26	Dihyrothienopyrimidines for the treatment of inflammatory diseases
PT2303021T (pt)	2019-04-01	Compostos para tratamento do cancro
IL193747A0 (en)	2009-08-03	New therapeutic combinations for the treatment of depression
SI2209784T1 (sl)	2013-02-28	Spojine za zdravljenje hepatitisa C
ZA201000923B (en)	2011-04-28	Compounds for the treatment of hepatitis c
IL204728A0 (en)	2010-11-30	Methods and compounds for treating retinol-related diseases
GB0909297D0 (en)	2009-07-15	Composition for the treatment of skin conditions
IL192933A0 (en)	2009-02-11	Benzoisoindole derivatives for the treatment of pain
EP2039392A4 (en)	2010-01-06	DEVICE FOR PHYSIOTHERAPY TREATMENT OF DISEASES OF VARIOUS AITIOLOGIES
ZA201001546B (en)	2010-10-27	Isoxazole compounds for the treatment of cancer
IL226363A0 (en)	2013-06-27	Compounds and methods for treating cancer
ZA200606780B (en)	2008-08-27	Compounds for the treatment of diseases
HK1137996A (en)	2010-08-13	3-imidazolyl-indoles for the treatment of proliferative diseases
GB0715255D0 (en)	2007-09-12	Thiadiazol-piperazinyl derivatives for the treatment of neurodegenerative diseases
ZA200806180B (en)	2009-07-29	Benzoisoindole derivatives for the treatment of pain
HK1133007A (zh)	2010-03-12	治療丙型肝炎的化合物